Lung cancer results when normal check and balance system of cell division is disrupted and ultimately the cells divide and proliferate in an uncontrollable manner forming a mass of cells in our body, known as tumor. Frequent mutations in Protein Kinase Domain alter the process of phosphorylation which results in abnormality in regulations of cell apoptosis and differentiation. Tyrosine Protein kinases and Serine/Threonine Protein Kinases are the two broad classes of protein kinases in accordance to their substrate specificity. The study of Tyrosine protein kinase and serine Kinase coding regions have the importance of sequence and structure determinants of cancer-causing mutations from mutation-dependent activation process. In the present study, we analyzed huge amounts of data extracted from various biological databases and NCBI. Out of the 534 proteins that may play a role in lung cancer, 71 proteins were selected that are likely to be actively involved in lung cancer. PrePrints ABSTRACT Lung cancer results when normal check and balance system of cell division is disrupted and ultimately the cells divide and proliferate in an uncontrollable manner forming a mass of cells in our body, known as tumor. Frequent mutations in Protein Kinase Domain alter the process of phosphorylation which results in abnormality in regulations of cell apoptosis and differentiation. Tyrosine Protein kinases and Serine/Threonine Protein Kinases are the two broad classes of protein kinases in accordance to their substrate specificity. The study of Tyrosine protein kinase and serine Kinase coding regions have the importance of sequence and structure determinants of cancer-causing mutations from mutation-dependent activation process.
INTRODUCTION
Lung cancer results when the body's system of checks and balances on the growth of cells is disrupted. This disruption results in uncontrolled division and proliferation of cells that ultimately form a mass of cells known as tumor. Cancers generally refer to those tumors which are malignant. The Protein Kinase family is the most frequently mutated gene family found in human Lung Cancers and kinases enzymes are widely targeted for the designing of anticancer drugs (Futreal et al., 2005) . Protein Kinase domain is an evolutionarily conserved domain comprising of Protein Kinases enzymes. These enzymes function efficiently in the process of Phosphorylation by transferring phosphate groups from nucleoside triphosphate donor to acceptor molecules. Cancer is the result of abnormal phosphorylation. Tyrosine kinases and Serine/Threonine Kinases constitute to form 2 broad classes of protein kinases differing with respect to their substrate specificity. A substantial percentage of Lung Cancers express Epidermal Growth Factor Receptors (EGFRs) (Sequist et al., 2007) ; a cell surface receptor and several clinical researches efforts are performed towards the development of inhibitors of EGFR. Clinical responses in non-small cell lung cancer patients with EGFR Tyrosine Kinase inhibitor, Gefitinib were found to correlate with the presence of somatic EGFR kinase domain mutations in tumors (Daub et al., 2004 , Lynch et al., 2004 , Paez et al., 2004 . Several other proteins that are considered to possess Protein Kinase Domain and are effectively responsible for the pathogenesis of Lung cancer include: BRAF, ERBB2,PTK2, TGFBR2, KDR, MET, IGF1R.MAPK1 and ALK. These proteins contain Protein Kinases ATP binding signatures and Tyrosine kinases specific active site signatures or Serine/Threonine Kinases specific active site signatures [ Table 2 ].In the present study, we focused on the proteins that are believed to have 15   16  17  18  19  20  21  22  23   24  25  26  27  28  29  30  31  32  33  34   35   36   37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 major role in pathogenesis of Lung Cancer by performing Domain and Motif study using Bioinformatics approach.
MATERIALS AND METHODS

2.1Sequence Retrieval from NCBI
We collected 71 known proteins that are actively involved in the pathogenesis of Lung cancer. The functional protein sequences in FASTA format for these proteins were retrieved from NCBI (National Center for Biotechnology Information: (http://www.ncbi.nlm.nih.gov) including their function, domain structure. Cross references with other databases modemize NCBI entries to hold details expertise.
Multiple Sequence Alignment
ClustalW is a widely used multiple sequence alignment (MSA) computer program. ClustalW is a general rationale multiplesequence alignment program for DNA or proteins (Chenna et al., 2003) . It finds out the most outstanding match for the selected sequences and aligns them up so that the identities, similarities and differences can be seen. These sequences were employed to ClustalW (http://www.ebi.ac.uk/clustalw) for multiple sequence alignment which calculates the best match for selected sequences and lines them up so that the identities, similarities and differences can be seen.
Development of Phylogenetic tree
The sequence analysis score shows a high degree of evolutionary conservation among the sequences of the proteins. The phylogenetic profile of the proteins depicts low substitution rate & less gap penalty which indicates that they belong to same protein family. The evolutionary tree was drawn using NEIGHBOR. A rooted Phylogenetic tree with a unique node corresponding to the most recent common ancestor was found using the evolutionary analysis study. Based on these results, the score table and Phylogenetic tree that shows the distance between the protein sequences were constructed [ Fig.1 ].
Identification of Domain and motif
Multiple Sequence Alignment was succeeded by Domain and Motif Study which revealed 10 proteins containing Protein Kinase domain and different Protein Kinases ATP binding signatures and Tyrosine Kinases specific active site signatures or Serine/Threonine Kinases specific active site signatures.
RESULTS AND DISCUSSION
The Bioinformatics analysis revealed 10 proteins out of 71 proteins that are key pathological proteins in the evolution of Lung Cancer. From the phylogenetic study we found that these 10 proteins are evolutionarily related. The present domain and motif study revealed that 10 proteins were found to contain Protein Kinase domain and Tyrosine Kinase specific or Serine/Threonine Kinase specific active-site signatures which include ALK, BRAF, EGFR, ERBB2,IGF1R, KDR, MAPK1, MET, PTK2 and TGFBR2. From Table -2 these proteins are mainly responsible for the lung cancer. From the above domain study, we found that these proteins have conserved domains. These domains have some conserved patterns and the active sites those are responsible for the proliferation of the lung cancer.
EGFR Mutations and Lung Cancer
In tumors from patients with NSCLC responsive to the tyrosine kinase inhibitor gefitinib, (Lynch et al., 2004) and (Paez et al., 2004) identified mutations in the EGFR gene. Paez et al., (2004) found somatic mutations in EGFR in 15 of 58 unselected NSCLC tumors from Japan and 1 of 61 from the United States. Pao et al., (2004) found that in-frame deletions in exon 19 of the EGFR gene and somatic point mutations in codon 858 (exon 21) were common particularly in lung cancers from 'never smokers' and were associated, as found by others, with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.
BRAF Mutations and Lung Cancer
Mutations of the BRAF protein serine/threonine kinase gene have been identified in a variety of human cancers, most notably melanomas. (Naoki et al., 2002) analyzed the BRAF sequence in 127 primary human lung adenocarcinomas and found mutations in 2 tumor specimens, one in exon 11 and another in exon 15. The specimens belonged to the same adenocarcinoma subgroup as defined by clustering of gene expression data. The authors proposed that BRAF may provide a target for anticancer chemotherapy in a subset of lung adenocarcinoma patients.
.ERBB2 Mutations and Lung Cancer
The Cancer Genome Project and Collaborative Group (2004) sequenced the ERBB2 gene from 120 primary lung tumors and identified 4% that had mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. In-frame deletions within the kinase domain of EGFR are associated with lung tumors that respond to therapy with gefitinib, an EGFR inhibitor. The Cancer Genome Project and Collaborative Group (2004) suggested that ERBB2 inhibitors, which had to that time proved to be ineffective in treating lung cancer, should be clinically reevaluated in the specific subset of patients with lung cancer whose tumors carry ERBB2 mutations.
ALK Mutations and Lung Cancer Soda et al., (2007) identified a fusion gene, ALK/EML4
, that was present in 5 of 75 Japanese non-small cell lung cancer patients examined. None of these patients had mutations in EGFR.
CONCLUSION
As research related to currently most advanced Lung cancer, reviewed the focuses on progress in the development and improve the diagnosis and treatment of Lungs cancer. It is evident from the discussion that ALK, BRAF, EGFR, ERBB2, IGF1R, KDR, MAPK1, MET, PTK2, TGFBR2 proteins play a significant role in the pathogenesis of lung cancer. Mutation in this particular EGFR, ERBB2, BRAF and ALK genes are responsible for the disease. From the domain study from Table2, we found that these proteins are having common Tyrosine protein kinases domain. This Tyrosine protein kinase domain is responsible for the disease prognosis. In tumors from patients with NSCLC responsive to the Tyrosine Kinase inhibitor Gefitinib, (Lynch et al., 2004) and (Paez et al., 2004) identified mutations in the EGFR gene. The present study resultswill be helpful for the identification and designing the drugs for the lung cancer.
Although clinical responses to some Tyrosine protein kinases inhibitors as a single agent have been observed in several clinical trials, there is evidence that some of these inhibitors are more effective if given concurrently or sequentially with chemotherapy such as taxol, carboplatin, cisplatin, and etoposide (Woodburn et al., 2000) (Lydon et al., 1998) (Baselga et al., 1998) (Pietras et al., 1998) (Pegram et al., 1999) (Demidem et al., 1997) (Ciardiello et al., 2000) . It is likely that several clinically useful Tyrosine protein kinases inhibitors will be in the market within the next decade, and that these new therapies will be more effective and with fewer side effects on patients with lung cancer.
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